Edition:
United States

Soligenix Inc (SNGX.OQ)

SNGX.OQ on NASDAQ Stock Exchange Capital Market

2.03USD
23 Feb 2018
Change (% chg)

$0.03 (+1.50%)
Prev Close
$2.00
Open
$2.00
Day's High
$2.04
Day's Low
$2.00
Volume
1,397
Avg. Vol
15,394
52-wk High
$5.07
52-wk Low
$1.77

Chart for

About

Soligenix, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical... (more)

Overall

Beta: 0.46
Market Cap(Mil.): $17.64
Shares Outstanding(Mil.): 8.73
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 195.87 16.59
EPS (TTM): -- -- --
ROI: -- -0.71 35.07
ROE: -- -3.37 17.79

BRIEF-Soligenix - Driving Towards Key Inflection Points With Two Pivotal Phase 3 Clinical Trials

* SOLIGENIX - DRIVING TOWARDS KEY INFLECTION POINTS WITH TWO PIVOTAL PHASE 3 CLINICAL TRIALS Source text for Eikon: Further company coverage:

Jan 25 2018

BRIEF-Soligenix Announces US Patent Issuance For Use Of Dusquetide In Oral Mucositis

* SOLIGENIX ANNOUNCES US PATENT ISSUANCE FOR USE OF DUSQUETIDE IN ORAL MUCOSITIS Source text for Eikon: Further company coverage:

Jan 02 2018

BRIEF-Soligenix Identifies Biomarkers For Ricin Toxin Vaccine Testing Under FDA Animal Rule

* SOLIGENIX IDENTIFIES BIOMARKERS FOR RICIN TOXIN VACCINE TESTING UNDER THE FDA ANIMAL RULE

Dec 21 2017

BRIEF-‍Knoll Capital Management LP​ reports a 9.9 pct passive stake in Soligenix as of Nov 2

* ‍Knoll Capital Management LP​ reports a 9.9 percent passive stake in Soligenix Inc as of Nov 2 - SEC Filing Source text: [http://bit.ly/2zVA43d] Further company coverage:

Nov 13 2017

BRIEF-‍ACT Capital Management reports 9.9 pct passive stake in Soligenix - SEC filing​

* ‍act Capital Management LLLP reports 9.9 percent passive stake in Soligenix Inc as of November 2, 2017 - SEC filing​ Source text: (http://bit.ly/2yFcZRO) Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

Nov 07 2017

BRIEF-Soligenix reports Q3 loss per share $0.17

* Soligenix announces recent accomplishments and third quarter 2017 financial results

Nov 06 2017

BRIEF-Soligenix Inc announces pricing of offering

* Soligenix announces pricing of $5,115,000 concurrent registered direct offering and private placement of common stock priced above market

Oct 31 2017

BRIEF-Soligenix receives $1.5 mln to support Phase 3 clinical trial of SGX301​

* Soligenix - ‍national Institutes of Health awarded co about $1.5 million over 2 years to support conduct of pivotal Phase 3 clinical trial evaluating SGX301​ Source text: (http://bit.ly/2yemsz3) Further company coverage:

Sep 29 2017

BRIEF-Soligenix announces $1.5 mln NIDCR SBIR grant award supporting the pivotal phase 3 clinical trial of SGX942

* Soligenix announces $1.5 million NIDCR SBIR grant award supporting the pivotal phase 3 clinical trial of SGX942 for the treatment of oral mucositis in head and neck cancer Source text for Eikon: Further company coverage:

Sep 20 2017

BRIEF-Soligenix announces $1.5 mln NCI SBIR grant award supporting the phase 3 clinical trial of SGX301 for the treatment of cutaneous t-cell lymphoma

* Soligenix announces $1.5 million NCI SBIR grant award supporting the pivotal phase 3 clinical trial of SGX301 for the treatment of cutaneous t-cell lymphoma Source text for Eikon: Further company coverage:

Sep 18 2017

Earnings vs. Estimates